Tunlametinib capsules are an oral targeted therapeutic agent for tumors harboring specific gene mutations, mainly indicated for the treatment of malignant tumors including unresectable or metastatic melanoma and non-small cell lung cancer (NSCLC).
Its core mechanism is the selective inhibition of MEK kinase, blocking the abnormal proliferation signaling pathway in tumor cells. Common adverse reactions include skin reactions and gastrointestinal symptoms. The drug must be administered strictly under medical supervision.
1. Indications and Mechanism of Action
Tunlametinib is indicated for patients with BRAF V600 mutation‑positive advanced solid tumors, and may be effective particularly in cases refractory or relapsed to other therapies.
By inhibiting MEK protein activity, it interferes with the RAS/RAF/MEK/ERK signaling pathway, thereby suppressing tumor growth and metastasis.
2. Dosage and Administration
Standard dosage:
Usually 2 mg orally once daily, with or without food. The dose should be adjusted according to the patient’s body weight, disease status, and tolerability.
Dosage adjustment:
If severe adverse reactions (e.g., hepatic injury, cardiomyopathy) occur, treatment should be interrupted or the dose reduced to 1 mg daily until symptoms resolve.
Missed dose:
If a dose is missed, no replacement dose is needed; resume the next scheduled dose as planned.
3. Adverse Reactions
Common reactions (incidence ≥ 20%):
Rash, diarrhea, fatigue, edema, nausea. These are usually mild to moderate and manageable with symptomatic treatment.
Serious reactions:
Cardiovascular toxicity: Decreased left ventricular ejection fraction, hypertension.
Hepatic injury: Manifested as elevated transaminases; liver function requires regular monitoring.
Ocular disorders: Retinal vein occlusion, blurred vision. Discontinue the drug immediately and seek medical help if these occur.
4. Drug Interactions
Strong CYP3A4 inhibitors (e.g., clarithromycin) may increase plasma concentrations of tunlametinib; co‑administration requires caution.
Anticoagulants (e.g., warfarin) may increase bleeding risk; coagulation function should be closely monitored during combination therapy.
5. Contraindications and Precautions
Contraindicated populations
Patients with hypersensitivity to any ingredient of the product.
Pregnant and lactating women.
Patients with severe hepatic or renal impairment (Child–Pugh Class C).
Important precautions
Confirm the presence of BRAF V600 mutation in tumor tissue before treatment initiation.
Fertile patients must use effective contraception during treatment and for 1 month after drug discontinuation.
Avoid excessive sun exposure, as the drug may increase the risk of photosensitivity dermatitis.
6. Storage and Shelf Life
Store protected from light at temperatures below 25 °C.
Keep the container tightly sealed and moisture‑proof after opening.
The shelf life is generally 24 months; refer to the package label for specifics.
7. Use in Special Populations
Pediatric use
Safety and efficacy have not been established; use requires careful evaluation.
Geriatric use
No routine dosage adjustment is needed, but adverse reactions should be monitored closely due to more frequent comorbidities.
Hepatic and renal impairment
Dose reduction is recommended for mild to moderate impairment; the drug is contraindicated in severe impairment.
The above information is for reference only. The specific treatment regimen must be prescribed by a physician based on the patient’s individual condition.
During treatment, regular follow‑up examinations of blood routine, liver and renal function, and cardiac function are required, and any abnormal symptoms should be reported promptly.
